

In the Claims:

This listing of claims will replace all prior versions and listings of claims in this application.

1-9 (cancelled).

10 (currently amended). A method for assessing the likelihood of a colon tumour metastasizing, comprising the steps of:

(a) determining the expression of 7a5/Prognostin in a biological sample from a tissue or a bodily fluid from a patient with a colon tumour; and

(b) comparing said expression with a control value,
that is based on the expression of 7a5/Prognostin in non-metastasizing tumours,
wherein an elevated 7a5/Prognostin expression in said biological sample compared to the control value indicates a greater likelihood that the colon tumour will metastasize, ~~and wherein the tumour is selected from a tumour of the intestines, liver, lymph nodes, lungs, bones or brain.~~

11 (previously presented). The method according to claim 10, wherein the determination of said expression of 7a5/Prognostin comprises a hybridisation, a PCR, a “real time” (RT)-PCR, an antigen-antibody binding, an ELISA, an optical proteome analysis, a one- or multi-dimensional gel electrophoresis, an analysis by mass spectrometry, a chromatography, a sequencing procedure, a methylation analysis, a SNP-determination or combination of these methods.

12 (canceled).

13 (currently amended). The method according to claim 10, wherein said biological sample is derived from a tumour biopsy from the colon, ~~rectum, or breast,~~ or from the bodily fluid of a subject having at least one of said colon tumours.

14-48 (cancelled).

49 (previously presented). A method for diagnosing whether a subject has cancer, comprising the steps of:

(a) determining the expression of 7a5/Prognostin in a biological sample from a tissue or bodily fluid of the subject; and
(b) comparing said expression with a control value that is based on the expression of 7a5/Prognostin in non-cancerous tissue or bodily fluid,
wherein an elevated 7a5/Prognostin expression in said biological sample compared to the control is indicative of the subject having cancer.

50 (previously presented). The method according to claim 49, wherein the determination of said expression of 7a5/Prognostin comprises a hybridisation, a PCR, a “real time” (RT)-PCR, an antigen-antibody binding, an ELISA, an optical proteome analysis, a one- or multi-dimensional gel electrophoresis, an analysis by mass spectrometry, a chromatography, a sequencing procedure, a methylation analysis, a SNP-determination or combination of these methods.